Related Experiment Videos
The effect of SERMs on the endometrium
1Department of Obstetrics and Gynecology, New York University School of Medicine, New York 10016, USA. Steven.Goldstein@Med.Nyu.Edu
Annals of the New York Academy of Sciences
|January 25, 2002
Summary
Tamoxifen effectively prevents breast cancer but increases endometrial cancer risk, particularly in women over 50. This selective estrogen receptor modulator (SERM) requires careful consideration for its benefits versus risks.
Area of Science:
- Oncology
- Pharmacology
- Gynecology
Background:
- Tamoxifen, a selective estrogen receptor modulator (SERM), is a widely used antineoplastic drug approved in 1978.
- It has demonstrated efficacy in various breast cancer settings and is used by millions of women.
- Initial research focused on tamoxifen's therapeutic effects in breast cancer patients.
Observation:
- Case reports in the 1980s suggested a link between tamoxifen and endometrial carcinoma.
- The National Surgical Adjuvant Breast and Bowel Project's (NSABP) P-1: Breast Cancer Prevention Trial (BCPT) was halted early due to tamoxifen's breast cancer prevention benefits.
- The BCPT provided crucial data on tamoxifen's effects in healthy women without prior breast cancer.
Findings:
- In healthy women, tamoxifen use was associated with a 2.54-fold increased risk of endometrial carcinoma.
- Stratification by age revealed a significantly higher risk (4.01-fold) in women over 50.
- Women under 50 did not show a statistically significant increase in endometrial carcinoma risk.
Implications:
- Tamoxifen's benefits in breast cancer prevention must be weighed against the increased risk of endometrial cancer, especially in postmenopausal women.
- The findings highlight the importance of age-specific risk assessment for tamoxifen therapy.
- Further research may explore risk mitigation strategies or alternative treatments for specific patient populations.